Open an account

Nurix Therapeutics

NRIX · NASDAQ

$26.10+$1.17 (+4.69%)TodayMarket closed ·
Prev close $24.93

About NRIX

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Brisbane California, California and currently employs 317 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The firm is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Employees
317
Headquarters
Brisbane California, California
Listed
Jul 24, 2020
Sector
Health Care
Industry
Biotechnology
Website
nurixtx.com

NRIX key statistics

Market cap
2.85B
Price-earnings ratio
10.84
Dividend yield
—
Average volume
2.23M
Volume
3.98M
Open price
$24.92
High today
$26.34
Low today
$24.71
52 Week high
$28.23
52 Week low
$9.93

Nurix Therapeutics (NRIX) at a glance

Nurix Therapeutics (NRIX) last traded at $26.10, with a market cap of 2.85B and a price-to-earnings ratio of 10.84.

Today the stock has traded between $24.71 and $26.34. The current price is 5.6% above the day's low and 0.9% below its high.

Volume so far is 3.98M shares, above the average of 2.23M shares a day.

Over the past year Nurix Therapeutics has ranged from $9.93 to $28.23, and now sits 88% of the way up that range.

Nurix Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY26 it reported $4.73 per share against an estimate of -$0.6129.

The average analyst price target is $34.92, 33.8% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 13 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $34.92
Low
$25.25
Now
$26.10
High
$47.25

NRIX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 230.9% on average.

  1. Q4 FY24: reported -$0.75 per share against an estimate of -$0.6903
  2. Q1 FY25: reported -$0.67 per share against an estimate of -$0.7788
  3. Q2 FY25: reported -$0.52 per share against an estimate of -$0.744
  4. Q3 FY25: reported -$1.03 per share against an estimate of -$0.858
  5. Q4 FY25: reported -$0.82 per share against an estimate of -$0.888
  6. Q1 FY26: reported -$0.79 per share against an estimate of -$0.7694
  7. Q2 FY26: reported -$0.81 per share against an estimate of -$0.7312
  8. Q3 FY26: reported $4.73 per share against an estimate of -$0.6129

NRIX news

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Rishabh Mishra

    Stock Market: Will S&P 500 Open Up or Down Today?

  • Press releasePRNewswire

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

  • Vandana Singh

    Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

  • What 11 Analyst Ratings Have To Say About Nurix Therapeutics

  • Press releasePRNewswire

    Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

  • Press releaseGlobe Newswire

    Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

  • What 18 Analyst Ratings Have To Say About Nurix Therapeutics

Similar companies

Companies in the same industry as Nurix Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.